Takeda Pharmaceuticals International Co., London, UK.
Faculty of Biology, Medicine, and Health, Division of Population Health, Health Services Research, and Primary Care, School of Health Sciences, Manchester Centre for Health Economics, University of Manchester, Manchester, UK.
J Med Econ. 2020 Oct;23(10):1176-1185. doi: 10.1080/13696998.2020.1796360. Epub 2020 Jul 30.
To construct and compare a partitioned-survival analysis (PartSA) and a semi-Markov multi-state model (MSM) to investigate differences in estimated cost effectiveness of a novel cancer treatment from a UK perspective.
Data from a cohort of late-stage cancer patients ( > 700) enrolled within a randomized, controlled trial were used to populate both modelling approaches. The statistical software was used to fit parametric survival models to overall survival (OS) and progression-free survival (PFS) data to inform the PartSA (package "flexsurv"). The package "mstate" was used to estimate the MSM transitions (permitted transitions: (T1) "progression-free" to "dead", (T2) "post-progression" to "death", and (T3) "pre-progression" to "post-progression"). Key costs included were treatment-related (initial, subsequent, and concomitant), adverse events, hospitalizations and monitoring. Utilities were stratified by progression. Outcomes were discounted at 3.5% per annum over a 15-year time horizon.
The PartSA and MSM approaches estimated incremental cost-effectiveness ratios (ICERs) of £342,474 and £411,574, respectively. Scenario analyses exploring alternative parametric forms provided incremental discounted life-year estimates that ranged from +0.15 to +0.33 for the PartSA approach, compared with -0.13 to +0.23 for the MSM approach. This variation was reflected in the range of ICERs. The PartSA produced ICERs between £234,829 and £522,963, whereas MSM results were more variable and included instances where the intervention was dominated and ICERs above £7 million (caused by very small incremental QALYs).
Structural uncertainty in economic modelling is rarely explored due to time and resource limitations. This comparison of structural approaches indicates that the choice of structure may have a profound impact on cost-effectiveness results. This highlights the importance of carefully considered model conceptualization, and the need for further research to ascertain when it may be most appropriate to use each approach.
构建并比较分区生存分析(PartSA)和半马尔可夫多状态模型(MSM),以从英国视角研究新型癌症治疗方案的成本效果估计差异。
来自一项纳入晚期癌症患者的随机对照试验队列的数据( > 700 名)被用于填充这两种模型方法。统计软件用于拟合总体生存(OS)和无进展生存(PFS)数据的参数生存模型,以告知 PartSA(“flexsurv”包)。使用“mstate”包来估计 MSM 转移(允许的转移:(T1)“无进展”至“死亡”,(T2)“后进展”至“死亡”,以及(T3)“前进展”至“后进展”)。关键成本包括与治疗相关的成本(初始、后续和伴随的)、不良事件、住院和监测。效用按进展分层。结果在 15 年的时间范围内以每年 3.5%贴现。
PartSA 和 MSM 方法分别估计增量成本效果比(ICER)为 342474 英镑和 411574 英镑。探索替代参数形式的情景分析提供了增量折扣生命年估计值,对于 PartSA 方法,范围从 0.15 到 0.33,而对于 MSM 方法,范围从 0.13 到 0.23。这种差异反映在 ICER 范围中。PartSA 产生的 ICER 在 234829 英镑至 522963 英镑之间,而 MSM 的结果则更加多变,包括干预措施被主导和 ICER 超过 700 万英镑的情况(这是由于非常小的增量 QALY 引起的)。
由于时间和资源的限制,经济建模中的结构不确定性很少被探索。这种结构方法的比较表明,结构的选择可能对成本效果结果产生深远影响。这凸显了仔细考虑模型概念化的重要性,以及需要进一步研究以确定何时最适合使用每种方法。